Prevalence and type distribution of human papillomavirus in healthy Japanese women aged 20 to 25 years old enrolled in a clinical study.
Efficacy, immunogenicity and tolerability of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine were evaluated in Japanese women aged 20-25 years, for which results have been reported previously. We analyzed the baseline data from that study and report the prevalence rates of HPV infection in young healthy Japanese women. One thousand and the forty Japanese women aged 20-25 years were enrolled in a phase II, double-blind, controlled, randomized, multicenter study. At study entry, cervical specimens were collected from the women and tested by line probe assay for 25 HPV-types and by HPV-16/18-specific polymerase chain reaction. The most frequently detected HPV-type in baseline cervical specimens was HPV-52 (8.1%), followed by HPV-16 (6.5%), HPV-51 (4.5%), HPV-18 (4.0%) and HPV-31 (3.8%). The proportion of HPV DNA-positive women increased with severity of cytological abnormalities: 26.1% (237/908) in normal cytology, 93.3% (70/75) in low-grade squamous intraepithelial lesion and 100% (7/7) in high-grade squamous intraepithelial lesion. The relative contribution of HPV-16 and HPV-18 was 4.1 and 3.0% for normal cytology cases, and 20.0 and 16.0% in low-grade squamous intraepithelial lesion, respectively. HPV-16 was found in four of seven high-grade squamous intraepithelial lesion cases (57.1%) and five of the six cervical intraepithelial neoplasia 2+ cases (83.3%). Multiple and single HPV infections were observed in 13.5% (140/1039) and 20.7% (215/1039) of all women, respectively. The HPV prevalence rates in Japanese women aged 20-25 years underline the importance of HPV vaccination at a young age and this report should be useful for monitoring changes in HPV prevalence after widespread HPV vaccination in Japanese women.
Department of Obstetrics and Gynecology, Jichi Medical University, Saitama Medical Center, Saitama, Japan. kryo772007@yahoo.co.jp
Ryo
R
Konno
Shinobu
S
Tamura
Kurt
K
Dobbelaere
Hiroyuki
H
Yoshikawa
D000328:Adult; D002584:Cervix Uteri / Q000473:pathology; D004279:DNA, Viral / Q000235:genetics; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D027383:Papillomaviridae / Q000145:classification* / Q000235:genetics; D030361:Papillomavirus Infections / Q000453:epidemiology* / Q000517:prevention & control / Q000821:virology; D053918:Papillomavirus Vaccines / Q000627:therapeutic use*; D016133:Polymerase Chain Reaction; D015995:Prevalence; D015996:Survival Rate; D016896:Treatment Outcome; D002578:Uterine Cervical Dysplasia / Q000453:epidemiology* / Q000517:prevention & control / Q000821:virology; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology* / Q000517:prevention & control / Q000821:virology; D014611:Vaccination; D014626:Vaginal Smears; D016387:Women's Health; D055815:Young Adult
D004279:DNA, Viral; D053918:Papillomavirus Vaccines
Lancet. 2007 Jun 2;369(9576):1861-1868
17544766
Lancet. 2009 Jul 25;374(9686):301-14
19586656
Gynecol Oncol. 2008 Sep;110(3 Suppl 1):S1-10
18653222
Vaccine. 2008 Aug 19;26 Suppl 12:M30-42
18945412
J Infect Dis. 2009 Apr 1;199(7):936-44
19236277
Int J Gynecol Cancer. 2008 Jan-Feb;18(1):71-9
17466054
Curr Opin Obstet Gynecol. 2009 Dec;21(6):457-64
19923989
Lancet. 2007 Jun 30;369(9580):2161-2170
17602732
Eur J Cancer. 2009 Oct;45(15):2632-9
19709878
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
15761078
Lancet. 2006 Apr 15;367(9518):1247-55
16631880
J Infect Dis. 2009 Apr 1;199(7):926-35
19236279
Drugs. 2010 Jun 18;70(9):1079-98
20518577
Gynecol Oncol. 2008 May;109(2 Suppl):S40-7
18482558
Int J Gynecol Cancer. 2006 May-Jun;16(3):1007-13
16803477
Vaccine. 2008 Aug 19;26 Suppl 12:M89-98
18945418
JAMA. 2007 Feb 28;297(8):813-9
17327523
Sex Transm Dis. 2008 Mar;35(3):276-82
18091564
Lancet. 2004 Nov 13-19;364(9447):1757-65
15541448
Cancer Sci. 2009 Jul;100(7):1312-6
19432906
Jpn J Clin Oncol. 2007 Nov;37(11):884-91
17954470
Virology. 2004 Jun 20;324(1):17-27
15183049
N Engl J Med. 2003 Feb 6;348(6):518-27
12571259
Vaccine. 2008 Oct 9;26(43):5435-40
18706952
Hum Vaccin. 2009 May;5(5):332-40
19221517
Gynecol Oncol. 2010 May;117(2 Suppl):S11-4
20129652
Int J Cancer. 2007 Aug 1;121(3):621-32
17405118
Vaccine. 2006 Jul 7;24(27-28):5571-83
16753240
Int J Gynecol Cancer. 2010 Jul;20(5):847-55
20606533
Vaccine. 2009 Jul 9;27(32):4355-62
19515467
Int J Gynecol Cancer. 2009 Jul;19(5):905-11
19574783
J Infect Dis. 2004 May 15;189(10):1829-32
15122519
Eur J Cancer. 2000 Nov;36(17):2266-71
11072218
Int J Cancer. 2006 Dec 1;119(11):2713-5
16929495
Int J Gynecol Cancer. 2010 Apr;20(3):404-10
20375805
Lancet. 2009 Dec 12;374(9706):1975-85
19962185
Lancet Oncol. 2005 May;6(5):271-8
15863374
J Pathol. 1999 Sep;189(1):12-9
10451482
Vaccine. 2006 Mar 30;24 Suppl 1:S1-15
16406226